The effect of 5-HT 1A receptor ligands in a chronic mild stress model of depression

Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.
Neuropharmacology (Impact Factor: 5.11). 11/1995; 34(10):1305-10. DOI: 10.1016/0028-3908(95)00102-C
Source: PubMed


Antidepressant properties of 5-HT1A receptor ligands (the full agonist 8-OH-DPAT, the partial agonists ipsapirone and buspirone, and the selective antagonist WAY 100135) were studied in a chronic mild stress model of depression. In this model, rats subjected to a variety of mild stressors for a prolonged period of time show a substantial decrease in the consumption of a 1% sucrose solution (anhedonia), an effect being sensitive to repeated treatment with antidepressant drugs. In the present study we found that the stress-induced deficit in the sucrose intake was gradually reversed by chronic (3-5 weeks) administration of buspirone (2.5 and 5 mg/kg, i.p., b.i.d.) or WAY 100135 (10 mg/kg, s.c., b.i.d.), but not 8-OH-DPAT (0.5 mg/kg, s.c., b.i.d.) or ipsapirone (5 mg/kg i.p., b.i.d.). The magnitude of the effect of buspirone and WAY 100135 was comparable to that observed following similar administration of the antidepressant drugs imipramine (10 mg/kg i.p.) or citalopram (10 mg/kg i.p.). Increases in the sucrose intake following chronic treatment with buspirone, WAY 100135, imipramine and citalopram were specific to the stressed animals; the behaviour of control non-stressed animals was unchanged by any drug. These results suggest that buspirone and WAY 100135 may have antidepressant properties. Possible links between the anti-anhedonic effect of these drugs and their interaction with 5-HT1A receptors and/or the dopamine system are discussed.

Download full-text


Available from: Mariusz Papp
  • Source
    • "Fluoxetine (Jindal et al. 2013; Muscat et al. 1992; Mutlu et al. 2012), maprotiline (Muscat et al. 1992), minaserin (Cheeta et al. 1994), imipramine (Marston et al. 2011; Norman et al. 2012; Papp et al. 1996; Przegalinski et al. 1995), buspirone (Papp et al. 1996; Przegalinski et al. 1995), ipsapirone (Przegalinski et al. 1995), agomelatine (Bourin et al. 2004; Dagyte et al. 2011), risperidon (Marston et al. 2011), citalopram (Herrera-Perez et al. 2010; Przegalinski et al. 1995), escitalopram (Christensen et al. 2012), tianeptine (Mutlu et al. 2012) Social stress— repeated defeat "
    [Show abstract] [Hide abstract]
    ABSTRACT: Modelling of complex psychiatric disorders, e.g., depression and schizophrenia, in animals is a major challenge, since they are characterized by certain disturbances in functions that are absolutely unique to humans. Furthermore, we still have not identified the genetic and neurobiological mechanisms, nor do we know precisely the circuits in the brain that function abnormally in mood and psychotic disorders. Consequently, the pharmacological treatments used are mostly variations on a theme that was started more than 50 years ago. Thus, progress in novel drug development with improved therapeutic efficacy would benefit greatly from improved animal models. Here, we review the available animal models of depression and schizophrenia and focus on the way that they respond to various types of potential candidate molecules, such as novel antidepressant or antipsychotic drugs, as an index of predictive validity. We conclude that the generation of convincing and useful animal models of mental illnesses could be a bridge to success in drug discovery.
    Full-text · Article · Aug 2013 · Cell and Tissue Research
  • Source
    • "BUS showed reversal of stress induced deficit in the sucrose intake (anhedonia), a major symptom of depression.[14] Further it exhibited significant anxiolytic activity in Vogel's and the open-field tests and novelty-suppressed feeding in food-deprived rats.[1516] It indicated significant mood regulating activity of BUS possibly by modulating 5-HT1A receptors in brain areas. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Depression is a neurological disorder characterized by sad mood, loss of pleasure, agitation and retardation. Though most relevant neuronal pathophysiology is characterized by decrease in monoamine namely; serotonin (5-HT), dopamine, noradrenaline level in central areas regulating mood and behavior, it inadequately explains the exact mechanism involved. Buspirone (BUS), a partial 5-HT1A receptor agonist has shown promising anti-depressant and anxiolytic properties in various pre-clinical and clinical studies, but the molecular and cellular mechanisms are still unclear. The aim of this study was to investigate, in vivo, the role of hypothalamic-pituitary-adrenal (HPA) axis dysregulation in pathophysiology of depression-related disorders and the anti-depressant like activity of BUS. To simulate HPA axis dysregulation, rats were subjected to bilateral adrenalectomy (ADX). We have analyzed effect of BUS (10 mg/kg, i.p.) in ADX and sham rats using open field, sucrose consumption, elevated plus maze and hyper-emotionality tests. In all animal models tested, ADX rats exhibited significant depressive and anxiogenic states while BUS was effective in reversing the psychological diseased condition developed. Taken together, these data showed a prominent role of HPA axis in depression and neuronal mechanism of BUS as anti-depressant and anxiolytic agent. Moreover, our findings suggest that BUS can be a better candidate for stress related depression and anxiety.
    Full-text · Article · Jul 2013 · Indian Journal of Psychological Medicine
  • Source
    • "Stress protocol, animal groups, and drug administration Forty-two male rats (180–220 g) were used in the chronic mild stress (CMS) experiment. According to a modification of the methods reported in previous studies (Willner et al. 1987; D'Aquila et al. 1997; Sowa-Kucma et al. 2008; Przegalí nski et al. 1995), animals were first trained to consume 1% (w/v) sucrose solution and then subjected to a baseline sucrose preference test before the start of the CMS protocol. After the baseline test, the animals were assigned to two groups matched on the basis of sucrose preference: control group (n = 10) and stressed group. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Total saponins extracted from the caudexes and leaves of Panax notoginseng (SCLPN) have been used in the clinic for improving mental function, treating insomnia, and alleviating anxiety. The present study evaluated the potential antidepressant activity of SCLPN in rodent models of depression and the mechanism of action of SCLPN. Mice were received SCLPN at doses of 10-1000 mg/kg daily for 1, 7, and 14 days and then were subjected to the forced swim test and locomotor activity test. The results showed that SCLPN decreased immobility time in the forced swim test, with little effect on locomotion. In the chronic mild stress model, chronic SCLPN treatment (70 mg/kg) reversed the rats' depression-like behavior. Furthermore, SCLPN exerted its antidepressant-like effect by increasing the levels of 5-hydroxytryptamine, dopamine, and noradrenaline. Additionally, SCLPN treatment reduced intracellular Ca(2+) in cultured neurons. The present study suggests that SCLPN may function as an antidepressant, and the antidepressant-like effects of SCLPN may be mediated by modulation of brain monoamine neurotransmitters and intracellular Ca(2+) concentration.
    Full-text · Article · Jun 2011 · Phytomedicine: international journal of phytotherapy and phytopharmacology
Show more